BAK trades 37.5% above Wall Street's consensus target of $1.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BAK achieves its forward estimates and maintains a stable P/E multiple of 1.1x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Braskem S.A. (BAK) has a Wall Street consensus price target of $1.50, based on estimates from 6 covering analysts. With the stock currently trading at $2.40, this represents a potential downside of -37.5%. The company has a market capitalization of $956M.
Analyst price targets range from a low of $1.50 to a high of $1.50, representing a 0% spread in expectations. The median target of $1.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, BAK trades at a trailing P/E of -0.5x and forward P/E of 1.1x. Analysts expect EPS to grow +109.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
LYBLyondellBasell Industries N.V. | $17.6B | $54.60 | $79.40 | +45.4% | Hold | 6.0x | 39 |
WLKWestlake Corporation | $9.8B | $76.27 | $114.00 | +49.5% | Hold | 20.3x | 32 |
OLNOlin Corporation | $2.4B | $20.74 | $28.30 | +36.5% | Hold | 292.9x | 35 |
TROXTronox Holdings plc | $976M | $6.12 | $8.33 | +36.1% | Buy | — | 17 |
AVNTAvient Corporation | $3.5B | $38.10 | $46.71 | +22.6% | Buy | 12.4x | 20 |
DOWDow Inc. | $20.6B | $28.64 | $37.55 | +31.1% | Hold | 9.3x | 35 |
LINLinde plc | $249.4B | $538.23 | $562.14 | +4.4% | Buy | 30.1x | 28 |
EMNEastman Chemical Company | $8.0B | $69.62 | $79.44 | +14.1% | Buy | 10.9x | 35 |
CECelanese Corporation | $5.4B | $48.68 | $65.60 | +34.8% | Hold | 7.9x | 37 |
HUNHuntsman Corporation | $1.9B | $10.97 | $13.60 | +24.0% | Hold | — | 33 |
Quick answers to the most common questions about buying BAK stock.
BAK's consensus price target is $1.5, -37.5% below the current price of $2.4. The 6 analysts tracking BAK see downside risk at present valuations.
BAK has a consensus rating of "Hold" based on 6 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $1.5 implies -37.5% downside from current levels.
With a forward P/E of 1.0627x, BAK trades at a relatively low valuation. The consensus target of $1.5 implies -37.5% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $1.5 for BAK, while the most conservative target is $1.5. The consensus of $1.5 represents the median expectation. These targets typically reflect 12-month expectations.
BAK is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BAK stock forecast based on 6 Wall Street analysts shows a consensus price target of $1.5, with estimates ranging from $1.5 (bear case) to $1.5 (bull case). The median consensus rating is "Hold".
BAK trades at a forward P/E ratio of 1.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on BAK, with 1 Sell ratings and a price target of $1.5 (-37.5% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BAK analyst price targets range from $1.5 to $1.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.